Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-08-29
Grafton and colleagues combined high-content imaging, induced pluripotent stem cell-derived cardiomyocytes, and deep learning to identify cardiotoxic phenotypes across chemically diverse compounds. The resulting single-parameter score provides a scalable early-screening strategy, while the study also shows why computational prioritization should be followed by orthogonal mechanistic validation.
-
Entinostat: From HDAC Target to Assay Insight
2026-08-28
Entinostat (MS-275) is a selective class I HDAC inhibitor whose value depends on linking target engagement to time-, tissue-, and phenotype-specific outcomes. This article uses axolotl regeneration research to develop a more rigorous framework for cancer cell proliferation inhibition, retinoblastoma treatment research, and translational assay design.
-
Cytochalasin B: Actin Assay Workflows
2026-08-28
Cytochalasin B is a reversible, cell-permeable probe for separating actin-dependent effects on migration, uptake, and cytokinesis from broader loss of cell fitness. This workflow-centered guide combines dose finding, washout controls, orthogonal viability readouts, and lessons from integrated genotoxicity testing to improve reproducibility in cytoskeletal assays.
-
Cefazedone PK/PD: From MIC to Clinical Design
2026-08-27
Cefazedone (Refosporen) is examined through an exposure-aware framework that connects MIC testing, protein binding, and time-dependent pharmacodynamics. This guide translates clinical PK/PD evidence into practical assay and translational study decisions.
-
Hydroxytyrosol: From Redox Signal to Assay Design
2026-08-27
Hydroxytyrosol is an olive-derived antioxidant bioactive compound with value in oxidative stress modulation and cardiovascular health research. This article translates comparative polyphenol findings into a rigorous framework for selecting cellular models, paired readouts, controls, and interpretation strategies.
-
BRD4–RAC1 Co-targeting in Breast Cancer
2026-08-26
The reference study identifies combined BRD4 and RAC1 inhibition as a context-dependent strategy that suppresses breast cancer growth, stemness, migration, and xenograft tumorigenesis. Its mechanistic contribution is the connection of BRD4–RAC1 signaling to the c-MYC–G9a–FTH1 and HDAC1–acetylated H3K9 axes, providing a framework for studying coordinated transcriptional and chromatin disruption across breast cancer subtypes.
-
MFGE8 Nanomedicine for Pancreatic Fibrosis
2026-08-26
The reference study traces an antifibrotic mechanism from umbilical cord-derived mesenchymal stem cells and their extracellular vesicles to MFGE8-dependent regulation of the ANXA1-SMAD2/3 pathway. It also translates that mechanism into a recombinant human MFGE8 nanoparticle platform, offering a cell-free strategy for chronic pancreatitis research while highlighting important questions about model fidelity, delivery, and clinical transferability.
-
(-)-JQ1: A Control for BRD4 Causal Inference
2026-08-25
(-)-JQ1 is an inactive JQ1 stereoisomer that helps separate BRD4-dependent biology from compound-independent effects. This article explains how to use it alongside genetic perturbation and the AKT-SIRT3 findings reported in hyperoxia-induced lung injury research.
-
PF-573228: A FAK Inhibitor Research Guide
2026-08-25
PF-573228 is an ATP-competitive FAK inhibitor with a reported biochemical IC50 of 4 nM. It is a research tool for testing FAK-dependent adhesion, migration, survival, angiogenesis, and mechanotransduction rather than a validated clinical treatment.
-
Halazone: A Redox-Aware Guide to Dual Assays
2026-08-24
Halazone is an antimicrobial sulfonamide derivative whose activity depends on oxidant availability, assay matrix, and exposure time. This guide connects water-disinfection performance with voltage-clamp evidence while defining practical controls, stability limits, and interpretation safeguards.
-
HotStart qPCR Master Mix for Cell Assays
2026-08-24
This scenario-driven guide shows how HotStart™ Universal 2X FAST Green qPCR Master Mix (Rox), SKU K1172, can strengthen gene expression readouts in cell viability, proliferation, and cytotoxicity workflows. It covers inhibitor tolerance, ROX compatibility, melt-curve verification, protocol setup, interpretation, and practical supplier selection.
-
AEBSF.HCl in Protease and Necroptosis Assays
2026-08-23
AEBSF.HCl is an irreversible serine protease inhibitor with applications spanning amyloid precursor protein processing, cell lysis, and mechanistic necroptosis assays. This guide focuses on a critical experimental distinction: suppressing serine proteases is not equivalent to blocking lysosomal cathepsin B.
-
Antibiotic-Resistant E. coli in Hanoi Rodents
2026-08-22
This study characterizes antimicrobial-resistant Escherichia coli carried by urban rodents in Hanoi, Vietnam, linking phenotypic resistance with multidrug resistance, ESBL production, colistin resistance, and a diarrheagenic E. coli-associated gene. Its findings support rodents as useful sentinels for environmental AMR surveillance while showing why isolate-level resistance data should not be interpreted as evidence of direct zoonotic transmission or clinical treatment failure.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-08-21
The reference study identifies Cdc2-like kinase 2 (CLK2) as a clinically relevant mediator of platinum resistance in ovarian cancer and connects its activity to BRCA1 Ser1423 phosphorylation and DNA damage repair. Its tissue, cell, and xenograft evidence supports CLK2 as a mechanistic target, while also defining important limits when translating CLK-family pharmacology into therapeutic studies.
-
Levofloxacin Workflows for Resistance and Bone Assays
2026-08-20
Levofloxacin connects bacterial DNA replication studies with controlled investigations of osteoblast and cartilage biology. This practical guide translates resistance-surveillance findings into assay design, preparation, optimization, and troubleshooting decisions.